Rescription, Inc., a leading innovator in pharmacy benefit management, is proud to announce it has been awarded a U.S. utility patent for its proprietary claims adjudication technology that enables 340B pricing to be applied in real-time at the point-of-sale.

This patent solidifies Rescription’s leadership in redefining prescription drug cost containment through its groundbreaking High-Cost Drug Program. The patented technology, built into Rescription’s Rexi™ platform, evaluates prescription claims in real time, identifying eligibility for 340B pricing based on specific drug, pharmacy, and patient criteria. When all requirements are met, the claim is automatically adjudicated leveraging the 340B acquisition cost, delivering meaningful savings compared to traditional, transparent, and pass-through PBM pricing models.

“This patent validates what our clients and partners have already experienced: that Rescription’s technology is fundamentally changing how pharmacy benefits can be delivered,” said Scott Martin, Founder and CEO of Rescription. “By bringing real-time 340B adjudication to the point-of-sale, we’re helping employers, health systems, and members unlock immediate, sustainable savings with radical clarity and the lowest price drug delivered every time.”

The High-Cost Drug Program, powered by this patented engine, has already demonstrated significant savings for self-insured employers by rerouting high-cost prescriptions through health system partners qualified under the federal 340B program. The platform’s intelligent logic integrates with real-time EMRs and pharmacy data to ensure compliance with 340B eligibility standards while removing administrative barriers that have historically limited access to these savings.

As drug costs continue to rise and traditional PBM models face increasing scrutiny, Rescription’s innovation represents a new standard in transparency, savings, and member care.

For more information about Rescription or its patented technology, visit www.rescription.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260203242991/en/

This patent validates what our clients and partners have already experienced: that Rescription’s technology is fundamentally changing how pharmacy benefits can be delivered.